Thermo Fisher Scientific’s innovation strategy
Thermo Fisher Scientific (TMO) has mostly grown through strategic mergers and acquisitions. It has also consistently invested in research and development (or R&D) to enhance its acquired product portfolio as well as to develop new products.
Thermo Fisher Scientific’s R&D investments comprise ~4% of its total revenues. In 2Q16, the company registered organic revenue growth of ~4%.
Among TMO’s peers, Abbott Laboratories (ABT), Becton Dickinson (BDX), and Baxter International (BAX) invested approximately 6.4%, 6.5%, and 5.8% of their total revenues, respectively, toward R&D in their most recent quarters.
The iShares Russell 1000 Value ETF (IWD) invests ~0.33% of its total holdings in Thermo Fisher Scientific.
Recent product approvals
On September 19, 2016, Thermo Fisher Scientific (TMO) launched a new sample purification system called KingFisher Presto. TMO noted that KingFisher Presto “automates the isolation of target nucleic acids and proteins for biopharma, biotech and research projects in high-throughput laboratories.”
According to Thermo Fisher Scientific, “The Thermo Scientific KingFisher Presto system is designed to be part of an automated workflow using a liquid handler with a gripper or robot arm to purify samples with volumes from 50µL to 5mL.
“The instrument’s small footprint allows for easy connection to several liquid handling instruments in either a side-by-side or on-deck configuration, allowing flexible selection of platform and use for a wide variety of applications.”
In August 2016, Thermo Fisher Scientific (TMO) received approval from the FDA for the EliA anti-thyroglobulin and anti-thyroid peroxidase tests for autoimmune thyroid disease. The company also received FDA clearance for a new immunoassay for the specific detection of hydrocodone. Hydrocodone is used to treat moderate to severe pain. TMO has a large number of generic and branded generic products in the market.
Next, let’s discuss the company’s recently completed FEI acquisition.